Key Points
- Tenet Healthcare director Nadja West sold 3,000 shares on May 27 at an average price of $177.35, generating about $532,050. After the sale, she still held 24,805 shares valued at roughly $4.4 million.
- The company reported stronger-than-expected quarterly earnings, posting $4.82 EPS versus the $4.21 analyst estimate, while revenue came in at $5.37 billion. Tenet also raised its FY 2026 guidance to 16.38-18.68 EPS.
- Wall Street remains broadly positive on THC, with 19 Buy ratings and 3 Hold ratings, giving it a consensus Moderate Buy and an average target price of $244.16.
Tenet Healthcare Corporation (NYSE:THC - Get Free Report) Director Nadja West sold 3,000 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $177.35, for a total transaction of $532,050.00. Following the completion of the transaction, the director owned 24,805 shares in the company, valued at $4,399,166.75. The trade was a 10.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Tenet Healthcare Stock Performance
Shares of THC opened at $173.45 on Friday. Tenet Healthcare Corporation has a 52 week low of $146.60 and a 52 week high of $247.21. The company has a quick ratio of 1.30, a current ratio of 1.36 and a debt-to-equity ratio of 1.96. The stock has a market cap of $14.94 billion, a price-to-earnings ratio of 9.02, a PEG ratio of 1.19 and a beta of 1.30. The business has a 50-day simple moving average of $190.50 and a two-hundred day simple moving average of $202.06.
Tenet Healthcare (NYSE:THC - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported $4.82 earnings per share for the quarter, beating analysts' consensus estimates of $4.21 by $0.61. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The firm had revenue of $5.37 billion for the quarter, compared to analysts' expectations of $5.39 billion. During the same period in the previous year, the firm earned $4.36 EPS. The business's quarterly revenue was up 2.6% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. On average, analysts expect that Tenet Healthcare Corporation will post 17.67 EPS for the current year.
Institutional Trading of Tenet Healthcare
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Wedmont Private Capital grew its stake in shares of Tenet Healthcare by 2.5% during the 4th quarter. Wedmont Private Capital now owns 2,088 shares of the company's stock valued at $422,000 after acquiring an additional 50 shares during the period. Baron Wealth Management LLC grew its stake in shares of Tenet Healthcare by 4.8% during the 4th quarter. Baron Wealth Management LLC now owns 1,142 shares of the company's stock valued at $227,000 after acquiring an additional 52 shares during the period. PeakShares LLC boosted its stake in Tenet Healthcare by 3.3% in the 1st quarter. PeakShares LLC now owns 1,693 shares of the company's stock worth $319,000 after purchasing an additional 54 shares during the period. Sagespring Wealth Partners LLC boosted its stake in Tenet Healthcare by 3.6% in the 4th quarter. Sagespring Wealth Partners LLC now owns 1,573 shares of the company's stock worth $313,000 after purchasing an additional 55 shares during the period. Finally, Sanctuary Advisors LLC boosted its stake in Tenet Healthcare by 0.5% in the 1st quarter. Sanctuary Advisors LLC now owns 11,900 shares of the company's stock worth $2,246,000 after purchasing an additional 57 shares during the period. Institutional investors own 95.44% of the company's stock.
Wall Street Analyst Weigh In
THC has been the subject of a number of research reports. TD Cowen reissued a "buy" rating on shares of Tenet Healthcare in a research note on Thursday, February 12th. Stephens dropped their price target on Tenet Healthcare from $275.00 to $260.00 and set an "overweight" rating for the company in a research note on Monday, May 4th. UBS Group upped their price objective on Tenet Healthcare from $260.00 to $288.00 and gave the company a "buy" rating in a research report on Thursday, February 12th. Wells Fargo & Company decreased their price objective on Tenet Healthcare from $265.00 to $213.00 and set an "overweight" rating on the stock in a research report on Friday, May 1st. Finally, Truist Financial upped their price objective on Tenet Healthcare from $240.00 to $270.00 and gave the company a "buy" rating in a research report on Tuesday, February 17th. Nineteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Tenet Healthcare presently has a consensus rating of "Moderate Buy" and an average target price of $244.16.
Read Our Latest Research Report on Tenet Healthcare
About Tenet Healthcare
(
Get Free Report)
Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet's operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.
In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
